Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy

Technology appraisal guidance
Reference number: TA850
Published: 14 December 2022

Evidence

Supporting evidence

Evaluation report
Appraisal consultation committee papers (PDF 4.1 MB)

Published:

14 December 2022
Final appraisal determination committee papers (PDF 927 KB)

Published:

14 December 2022